How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A canadian experience

Clinical Therapeutics

Volumn 24, Issue 9, 2002, Pages 1466-1476

  Dewa, Carolyn S ^a,b   Remington, Gary ^a,b   Herrmann, Nathan ^a,c   Fearnley, Joan ^d   Goering, Paula ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d Brogan Inc   (Canada)

Author keywords

Antipsychotics; Atypical antipsychotics; Dementia; Schizophrenia

Indexed keywords

CHLORPROMAZINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; AGE; AGED; ARTICLE; CANADA; DEMENTIA; DRUG UTILIZATION; HEALTH CARE COST; HUMAN; OUTPATIENT; PRESCRIPTION; SCHIZOPHRENIA;

EID: 0036749817     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80050-9     Document Type: Article

References (38)

1. Caligiuri MP, Lacro JP, Jeste DV. Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol. 1999;19:322-328.
2. Kane JM, Woemer M, Lieberman J. Tardive dyskinesia: Prevalence, incidence, and risk factors. J Clin Psychopharmacol. 1988;8(Suppl 4):52S-56S.
3. Goeree R, O'Brien BJ, Goering P, et al. The economic burden of schizophrenia in Canada. Can J Psychiatry. 1999;44:464-472.
4. Regier DA, Boyd JH, Burke JD Jr, et al. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry. 1988;45:977-986.
5. Herrmann N. Recommendations for the management of behavioral and psychological symptoms of dementia. Can J Neurol Sci. 2001;28(Suppl 1):S96-S107.
6. Canadian Study of Health and Aging Work Group. Canadian Study of Health and Aging: Study methods and prevalence of dementia. Can Med Assoc J. 1994;150:899-913.
7. Paterson CJ, Gauthier S, Bergman H, et al. Canadian Consensus Conference on Dementia: A physician's guide to using the recommendations. Can Med Assoc J. 1999;160:1738-1742.
8. The Expert Consensus Panel for Agitation in Dementia. Treatment of agitation in older persons with dementia. Postgrad Med Special Report. 1998;special issue: 1-88.
9. Canada Health Act overview. Available at: http://www.hc-sc.gc.ca/medicare/chaover.htm. Accessed June 23, 2001.
10. National Health Expenditure Database, Canadian Institute for Health Information. Available at: http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_page=spend_nhex_e. Accessed September 5, 2001.
11. The DELTA Report Summary of Findings. Mississauga, Can: Glaxo Wellcome Inc; 2000.
12. Willison D, Grootendorst P, Hurley J. Variation in Pharmacare Coverage Across Canada. Hamilton, Can: McMaster University Centre for Health Economics and Policy Analysis; 1998. Research Working Paper 98-8.
13. Canada Health Act Annual Report 2000-2001. Available at: http://www.hc-sc.gc.ca/medicare/AnnualReports.htm. Accessed July 25, 2001.
14. Remington G, Kapur S. Atypical antipsychotics: Are some more atypical than others? Psychopharmacology. 2000;148:3-15.
15. Canadian Institute for Health Information. Health Care in Canada 2002. Available at: http://secure.cihi.ca/cihiweb/hcic/hcic.html. Accessed July 25, 2002.
16. Sweet RA, Pollock BG. New atypical antipsychotics. Experience and utility in the elderly. Drugs Aging. 1998;12:115-127.
17. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res. 1999;35(Suppl):S61-S66.
18. Dewa CS, Goering P. Lessons learned from trends in psychotropic drug expenditures in a Canadian province. Psychiatr Serv. 2001;52:1245-1247.
19. Frances A, Docherty JP, Kahn DA. Expert Consensus Guidelines Series. Treatment of schizophrenia. J Clin Psychiatry. 1996;57(Suppl 12B).
20. Dewa CS, Hoch JS, Goering P. Using forecasting models to estimate the effects of changes in the composition of claims for selective serotonin reuptake inhibitors on expenditures. Clin Ther. 2001;23:292-306.
21. Putting People First: The Reform of Mental Health Services in Ontario. Toronto: Ontario Ministry of Health and Long Term Care; 1992.
22. Goering P, Lin E, DeBoer DP. Mental health levels of need and variations in service use in Ontario inpatient utilization. In: Goel V, Williams J, Anderson G, et al, eds. Patterns of Health Care in Ontario: The ICES Practice Atlas 2nd Edition. Toronto: Institute for Clinical Evaluative Sciences; 1996:274-281.
23. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry. 1999;46:1396-1408.
24. Richardson MA, Haughland G, Craig TJ. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients. Am J Psychiatry. 1991;148:1322-1328.
25. Gregory C, McKenna P. Pharmacological management of schizophrenia in older patients. Drugs Aging. 1994;5:254-262.
26. de Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946-955.
27. Katz IR, Jeste DV, Mintzer JE, et al, for the Risperidone Study Group. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry. 1999;60:107-115.
28. Street JS, Clark WS, Gannon KS, et al, for the HGEU Study Group. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2000;57:968-976.
29. Tariot PN, Salzman C, Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther. 2000;22:1068-1084.
30. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316:363-369.
31. Jeste DV, Rockwell E, Harris MJ, et al. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry. 1999;7:70-76.
32. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc. 1999;47:716-719.
33. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000;157:1150-1155.
34. Mattes JA. Risperidone: How good is the evidence for efficacy? Schizophr Bull. 1997;23:155-161.
35. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:51-68.
36. Zito JM. Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. Psychiatr Clin North Am. 1998;21:181-202.
37. Waddington JL, O'Callaghan E. What makes an antipsychotic atypical? CNS Drugs. 1997;7:341-346.
38. Meltzer HY. Outcome in schizophrenia: Beyond symptom reduction. J Clin Psychiatry. 1999;60(Suppl 3):3-7.